← SynDRA
LAPACHONE
SynDRA canonical compound SYN0000816 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | E2F1 | IDO1 | TDO2 | TOP1 |
|---|
| Mechanism of action | topoisomerase inhibitor |
|---|
All known targets
- TOP1
- E2F1
- IDO1
- SIRT1
- TDO2
Mechanisms of action (all sources)
- topoisomerase inhibitor
- SIRT1 MODULATOR
- TOP1 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ACHE
- MAPK1
- MBNL1
- MPHOSPH8
- MTOR
- NFE2L2
- NFKB1
- NPSR1
- NQO1
- PIN1
- PMP22
- POLH
- POLI
- POR
- RAB9A
- RECQL
- RGS4
- SMAD3
- SMN1
- SNCA
- STAT3
- TDP1
- TDP2
- THPO
- THRB
- TOP2A
- TP53
- TST
- USP1
- MAPT
- MALT1
- ALDH1A1
- LMNA
- ALOX15
- ALOX15B
- APP
- ARSA
- ATAD5
- ATXN2
- BLM
Cross-references
Synonyms
- .beta.-lapachone
- ARQ-501
- Beta-lapachone
- Beta-lap-wj
- Lapachone, beta-
- MB-12066
- NSC-26326
- NSC-629749
- B-lapachone (obesity), Mazence
- Beta-lapachone (obesity), Mazence
- Beta-Lapachone
- ARQ 501
- SL 11001
- A-lapachone
- LAPACHONE, BETA
- AK-693/21096016
- 2,2-dimethyl-3,4-dihydrobenzo[h]chromene-5,6-dione
- 3,4-Dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione
- 3,4-Dihydro-2,2-dimethyl-2H-naphtho[1,2-B]pyran-5,6-dione
- NSC 26326
- 6N4FA2QQ6A
- NSC 629749
- 2H-Naphtho[1,2-b]pyran-5,6-dione, 3,4-dihydro-2,2-dimethyl-
- NSC26326
- NSC629749
- ARQ501
- CHEBI:10429
- 2H-Naphtho(1,2-b)pyran-5,6-dione, 3,4-dihydro-2,2-dimethyl-
- 2,2-dimethyl-3,4-dihydrobenzo(h)chromene-5,6-dione
- RefChem:567893
- DTXCID50119510
- 2,2-Dimethyl-3,4-dihydro-2H-benzo[h]chromene-5,6-dione
- .beta.-Lapachone
- MFCD01712233
- ARQ-501 (beta lapachone)
- MB12066
- ARQ-501;NSC-26326
- b-Lapachone (90%)
Look up LAPACHONE in the interactive SynDRA portal →